Petauri Unites Mtech Access and Delta Hat Under One Team--Petauri Evidence

Rapidly growing pharmaceutical services platform unveils new integrated structure for global evidence solutions.

NASHVILLE, Tenn., April 16, 2025 /PRNewswire/ -- Petauri, a leading purpose-built pharmaceutical services platform, announced today the launch of its newest business unit, Petauri Evidence, an innovative offering that unites the esteemed legacy businesses of Mtech Access and Delta Hat, along with its existing US health economics and outcomes research (HEOR) business. This strategic restructuring seamlessly brings together highly skilled and diverse teams across the globe to deliver comprehensive evidence generation and market access solutions to the pharmaceutical and life sciences industry.

Petauri Evidence is dedicated to helping pharmaceutical, biotechnology, and medical device companies generate and apply real-world evidence to inform healthcare decision-making. By integrating Mtech Access's established global pricing and market access expertise with Delta Hat's advanced analytics and health economics capabilities, Petauri Evidence is positioned to provide clients with deeper insights and more impactful strategies. Together, they create a comprehensive suite of highly technical and specialized services that deliver unparalleled value to Petauri clients globally and reinforce Petauri's commitment to delivering evidence-based solutions.

"Bringing together the strengths of Mtech Access and Delta Hat under Petauri Evidence represents an exciting evolution in our ability to support our clients," said Dan Renick, CEO of Petauri. "The combination of these 2 respected organizations enhances our capabilities in evidence generation, global payer engagement, and value communications—ultimately enabling better healthcare decisions."

David Niziol, Cofounder of Mtech Access, brings extensive experience in leading the application of health economic, value communication, and evidence strategies to facilitate successful access. He will now serve as President of Petauri Evidence. "This integration strengthens our ability to deliver actionable insights and real-world evidence that help clients navigate complex access and reimbursement challenges worldwide, ultimately enhancing patient access to life-changing therapies," said Niziol. "By integrating the expertise of Mtech Access and Delta Hat, along with our US HEOR colleagues, we can offer more innovative and robust evidence solutions that support our clients in demonstrating the true value of their products."

Anthony Hatswell, Founder of Delta Hat and newly named Chief Scientific Officer of Petauri Evidence, emphasized the benefits of this integration: "We are thrilled to bring Delta Hat's end-to-end analytical excellence and highly regarded health economic modelling capabilities into Petauri Evidence. This evolution allows us to further expand our specialists' capabilities and offer a broader range of insights that drive meaningful outcomes for healthcare stakeholders."

Petauri Evidence will continue to develop cutting-edge evidence strategies and solutions to support pharmaceutical and life sciences companies in navigating complex global healthcare landscapes. Clients can expect an enhanced suite of services designed to optimize product value and improve patient access to innovative therapies.

About Petauri

Petauri is a purpose-built pharmaceutical services platform based in Nashville, Tennessee. Founded by CEO Dan Renick in partnership with Oak Hill Capital, the platform is launching, acquiring, and combining best-in-class companies with recognized expertise in global market access, medical affairs, commercialization support, patient services, and data and analytics. Since it was founded in 2023, the platform has launched Petauri Advisors and acquired The Kinetix Group, the agencies of FORCE Communications, Mtech Access, Delta Hat, the agencies of the Brightly Network, and Formulary Insights, all now Powered by Petauri™. Over time, Oak Hill will invest more than $250 million of equity capital in this initiative from its latest fund (OHCP VI). The platform works with pharmaceutical and life sciences clients to improve patient outcomes by establishing the scientific, economic, humanistic, and societal value of medical advances. From strategy to implementation, Petauri seamlessly supports these clients with a wide range of innovative solutions that speed patient access to life-changing care. For more information, please visit www.petauri.com.

Media Contact:

Liz Gulino
Petauri
[email protected]
973-476-1751

SOURCE Petauri